Metastatic malignant melanoma associated with vitiligo-like depigmentation

Clinical and Experimental Dermatology

Volumn 34, Issue 2, 2009, Pages 209-211

  Wang, J R ^a   Yu, K J ^a   Juan, W H ^a   Yang, C H ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; TAMOXIFEN;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEPIGMENTATION; DISEASE ASSOCIATION; FACE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOMELANOSIS; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INGUINAL LYMPH NODE; LIMB; LYMPH NODE BIOPSY; MALE; MELANOMA; METASTASIS; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SKIN NODULE; TREATMENT RESPONSE; TRUNK; VITILIGO;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FATAL OUTCOME; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS; VITILIGO;

EID: 58549113157     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2008.02872.x     Document Type: Article

References (10)

1. Tobin DJ, Swanson NN, Pittelkow MR et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000 191 : 407 16.
2. Becker JC, Guldberg P, Zeuthen J et al. Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol 1999 113 : 1033 8.
3. Merimsky O, Shoenfeld Y, Baharav E et al. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo). Hum Antibodies Hybridomas 1996 7 : 151 6.
4. Daneshpazhooh M, Shokoohi A, Dadban A et al. The course of melanoma-associated vitiligo: report of a case. Melanoma Res 2006 16 : 371 3.
5. Rodriguez-Cuevas S, Lopez-Chavira A, Zepeda del Rio G et al. Prognostic significance of cutaneous depigmentation in Mexican patients with malignant melanoma. Arch Med Res 1998 29 : 155 8.
6. Harris J, Bines S, Das Gupta T. Therapy of disseminated malignant melanoma with recombinant alpha 2b-interferon and piroxicam: clinical results with a report of an unusual response-associated feature (vitiligo) and unusual toxicity (diffuse pulmonary interstitial fibrosis). Med Pediatr Oncol 1994 22 : 103 6.
7. Tsao H, Millman P, Linette GP et al. Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol 2002 138 : 799 802.
8. Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006 354 : 709 18.
9. Kiecker F, Hofmann M, Sterry W, Trefzer U. Vitiligo-like depigmentation as a presenting sign of metastatic melanoma. J Eur Acad Dermatol Venereol 2006 20 : 1135 7.
10. Schallreuter KU, Levenig C, Berger J. Vitiligo and cutaneous melanoma. A case study. Dermatologica 1991 183 : 239 45.